These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3187409)

  • 41. [The study of cell surface antigens in bladder tumors: ABH-isoantigen and Thomsen-Friedenreich antigen].
    Kobayashi H
    Hinyokika Kiyo; 1987 Apr; 33(4):535-44. PubMed ID: 3618425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Words of wisdom. Re: Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer.
    Ohno Y
    Eur Urol; 2014 Aug; 66(2):391. PubMed ID: 25305789
    [No Abstract]   [Full Text] [Related]  

  • 43. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 64 patients.
    Montie JE
    J Urol; 2005 Jun; 173(6):1920-1. PubMed ID: 15879778
    [No Abstract]   [Full Text] [Related]  

  • 44. ABH secretor status in patients with bladder tumours.
    Paterson PJ
    Urol Res; 1976; 4(4):147-50. PubMed ID: 1020066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histologic tumor growth pattern is significantly associated with disease-related survival in muscle-invasive transitional cell carcinoma of the urinary bladder.
    Krüger S; Noack F; Böhle A; Feller AC
    Oncol Rep; 2004 Sep; 12(3):609-13. PubMed ID: 15289845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.
    Dinney CP; Babkowski RC; Antelo M; Perrotte P; Liebert M; Zhang HZ; Palmer J; Veltri RW; Katz RL; Grossman HB
    J Urol; 1998 Oct; 160(4):1285-90. PubMed ID: 9751337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenotypically heterogeneous deletion of the ABH antigen from the transformed bladder urothelium. A scanning electron microscope study.
    De Harven E; He S; Hanna W; Bootsma G; Connolly JG
    J Submicrosc Cytol; 1987 Oct; 19(4):639-49. PubMed ID: 3430650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Determination of serum SCC antigen in transitional cell carcinoma of the bladder].
    Moreno Sierra J; Maestro de las Casas M; Ortega Heredia MD; Rodríguez Molina J; López Asenjo J; Blanco Jiménez E; Hermida Gutiérrez J; Esteban Fuertes M; Resel Estevez L
    Actas Urol Esp; 1994 Jan; 18(1):26-8. PubMed ID: 8191942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determination of DNA ploidy and ABH antigen reactivity in both frozen and formalin-fixed bladder tumor tissue.
    Malmström PU; Vasko J; Wester K; Busch C
    Urol Res; 1991; 19(6):357-9. PubMed ID: 1759329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison between the methods of indirect immunofluorescence and specific red cell adherence in detecting ABH iso-antigens in bladder carcinoma.
    Cooper HS; D'Elia FL
    Am J Clin Pathol; 1982 May; 77(5):548-54. PubMed ID: 7044101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CA125 for following up carcinoma of the bladder.
    Wiwanitkit V
    Urol Oncol; 2010; 28(2):226. PubMed ID: 20056459
    [No Abstract]   [Full Text] [Related]  

  • 53. Prognostic factors in bladder cancer. A pathologic, immunohistochemical, and DNA flow-cytometric study.
    Lopez-Beltran A; Croghan GA; Croghan I; Matilla A; Gaeta JF
    Am J Clin Pathol; 1994 Jul; 102(1):109-14. PubMed ID: 8037155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ABH cell surface isoantigens in invasive bladder carcinoma associated with schistosomiasis.
    El Adl MM; Yamase HT; Nieh PT; Mostofa AS; Hinz CF; Walzak MP
    J Urol; 1984 Feb; 131(2):249-51. PubMed ID: 6366249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluorescence methods for measuring the A, B, and H isoantigens on cytological material from bladder carcinoma.
    Borgström E; Wahren B; Gustafson H
    Urol Res; 1985; 13(2):43-5. PubMed ID: 3892840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course.
    Limas C; Lange P; Fraley EE; Vessella RL
    Cancer; 1979 Dec; 44(6):2099-107. PubMed ID: 509389
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular markers in the diagnosis and prognosis of bladder cancer.
    Lange PH; Limas C
    Urology; 1984 Apr; 23(4 Suppl):46-54. PubMed ID: 6369720
    [No Abstract]   [Full Text] [Related]  

  • 58. Relationship between blood groups and tumour grade, number, size, stage, recurrence and survival in patients with transitional cell carcinoma of the bladder.
    Raitanen MP; Tammela TL
    Scand J Urol Nephrol; 1993; 27(3):343-7. PubMed ID: 8290914
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of A, B and H(O) antigens in normal and neoplastic epithelium of the urinary bladder by the specific red cell adherence test (SRCA).
    Kato T
    Tohoku J Exp Med; 1977 Mar; 121(3):239-46. PubMed ID: 857340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimation of ABO(H) isoantigen expression in bladder tumors.
    Srinivas V; Orihuela E; Lloyd KO; Old LJ; Whitmore WF
    J Urol; 1985 Jan; 133(1):25-8. PubMed ID: 3964875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.